Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker BTEC(USD) LSE
ETF Ticker BTEK(GBP) LSE
ETF Ticker 2B70(EUR) F
ETF Ticker 2B70.DE(EUR) CXE
ETF Ticker BTEC.LS(USD) CXE
ETF Ticker BTEK.LS(GBP) CXE
ETF Ticker BTEC.L(GBP) LSE
ETF Ticker BTEK.L(GBP) LSE

Holdings detail for RGNX

Stock Name	Regenxbio Inc
Ticker	RGNX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US75901B1070
LEI	549300EOES47LATSET33

Show aggregate RGNX holdings

News associated with RGNX

REGENXBIO Inc. (NASDAQ:RGNX) Receives $28.38 Consensus PT from Analysts: REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective […] - 2025-09-16 03:06:58
REGENXBIO (NASDAQ:RGNX) Receives Buy Rating from HC Wainwright: REGENXBIO (NASDAQ:RGNX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $34.00 target price on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 243.78% from the stock’s current price. […] - 2025-09-10 03:00:56
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital: Chardan Capital restated their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a report released on Monday,Benzinga reports. They currently have a $52.00 target price on the biotechnology company’s stock. Several other analysts have also recently issued reports on RGNX. Royal Bank Of Canada lowered their price objective on shares of REGENXBIO […] - 2025-09-09 03:10:46
Mitsubishi UFJ Asset Management Co. Ltd. Boosts Holdings in REGENXBIO Inc. (NASDAQ:RGNX): Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 9.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,756 shares of the biotechnology company’s stock after purchasing an additional 2,326 shares during the period. […] - 2025-08-15 04:47:03
REGENXBIO (NASDAQ:RGNX) Price Target Lowered to $17.00 at Royal Bank Of Canada: REGENXBIO (NASDAQ:RGNX – Free Report) had its target price trimmed by Royal Bank Of Canada from $21.00 to $17.00 in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. A number of other analysts have also weighed in on the stock. Chardan […] - 2025-08-11 04:50:48
GSA Capital Partners LLP Grows Stake in REGENXBIO Inc. (NASDAQ:RGNX): GSA Capital Partners LLP raised its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 659.7% during the 1st quarter, HoldingsChannel reports. The firm owned 131,329 shares of the biotechnology company’s stock after acquiring an additional 114,043 shares during the quarter. GSA Capital Partners LLP’s holdings in REGENXBIO were worth $939,000 as of its most […] - 2025-08-01 05:32:51
REGENXBIO Inc. (NASDAQ:RGNX) Receives $31.63 Average PT from Analysts: Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price […] - 2025-07-30 04:58:51
Cerity Partners LLC Acquires New Stake in REGENXBIO Inc. (NASDAQ:RGNX): Cerity Partners LLC acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) during the 1st quarter, Holdings Channel reports. The fund acquired 31,846 shares of the biotechnology company’s stock, valued at approximately $228,000. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FNY […] - 2025-07-29 04:17:07
REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Sigma Planning Corp: Sigma Planning Corp lessened its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 3.9% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 35,860 shares of the biotechnology company’s stock after selling 1,450 shares during the period. Sigma Planning Corp’s holdings in REGENXBIO were worth $256,000 at the end of the […] - 2025-07-22 07:26:52
Brokerages Set REGENXBIO Inc. (NASDAQ:RGNX) PT at $31.63: Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price […] - 2025-07-03 04:22:55
Assenagon Asset Management S.A. Has $4.10 Million Stock Position in REGENXBIO Inc. (NASDAQ:RGNX): Assenagon Asset Management S.A. lowered its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 33.1% during the first quarter, HoldingsChannel.com reports. The firm owned 573,173 shares of the biotechnology company’s stock after selling 283,399 shares during the period. Assenagon Asset Management S.A.’s holdings in REGENXBIO were worth $4,098,000 at the end of the most […] - 2025-06-16 05:05:11
REGENXBIO (NASDAQ:RGNX) Given “Buy” Rating at Chardan Capital: Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $52.00 target price on the biotechnology company’s stock. A number of other brokerages also recently issued reports on RGNX. Wall Street Zen raised REGENXBIO from a […] - 2025-06-10 02:50:56
REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Rating of “Moderate Buy” from Brokerages: Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective […] - 2025-06-05 02:48:51
BNP Paribas Financial Markets Has $743,000 Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX): BNP Paribas Financial Markets raised its holdings in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 370.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 96,093 shares of the biotechnology company’s stock after acquiring an additional 75,652 shares during the quarter. BNP Paribas Financial Markets’ […] - 2025-05-23 04:58:51
REGENXBIO Inc. (NASDAQ:RGNX) Shares Acquired by Jane Street Group LLC: Jane Street Group LLC grew its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 325.3% during the fourth quarter, HoldingsChannel reports. The firm owned 164,911 shares of the biotechnology company’s stock after purchasing an additional 126,135 shares during the quarter. Jane Street Group LLC’s holdings in REGENXBIO were worth $1,275,000 as of its most […] - 2025-05-21 04:51:04
Graham Capital Management L.P. Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX): Graham Capital Management L.P. lifted its position in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 59.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,542 shares of the biotechnology company’s stock after purchasing an additional 10,677 shares during the quarter. Graham Capital Management […] - 2025-05-19 05:27:01
Critical Analysis: REGENXBIO (NASDAQ:RGNX) versus Novavax (NASDAQ:NVAX): REGENXBIO (NASDAQ:RGNX – Get Free Report) and Novavax (NASDAQ:NVAX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings. Risk & Volatility REGENXBIO has a beta of 1.11, […] - 2025-05-19 04:42:52
Tower Research Capital LLC TRC Acquires 10,714 Shares of REGENXBIO Inc. (NASDAQ:RGNX): Tower Research Capital LLC TRC increased its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 442.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,138 shares of the biotechnology company’s stock after acquiring an additional 10,714 shares during the […] - 2025-05-09 05:23:02
Norges Bank Makes New $3.47 Million Investment in REGENXBIO Inc. (NASDAQ:RGNX): Norges Bank purchased a new stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 449,400 shares of the biotechnology company’s stock, valued at approximately $3,474,000. Several other institutional investors and hedge funds also recently […] - 2025-04-11 05:13:01
Mitsubishi UFJ Asset Management Co. Ltd. Has $198,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX): Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 48.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 25,430 shares of the biotechnology company’s stock after buying an additional 8,267 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in […] - 2025-04-04 05:12:56
EntryPoint Capital LLC Invests $97,000 in REGENXBIO Inc. (NASDAQ:RGNX): EntryPoint Capital LLC acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 12,538 shares of the biotechnology company’s stock, valued at approximately $97,000. Other large investors have also bought and sold shares […] - 2025-03-31 05:24:54
REGENXBIO Inc. (NASDAQ:RGNX) Receives $33.88 Average Price Target from Brokerages: REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price […] - 2025-03-25 03:36:46
AlphaQuest LLC Trims Stake in REGENXBIO Inc. (NASDAQ:RGNX): AlphaQuest LLC decreased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 66.9% during the fourth quarter, Holdings Channel reports. The fund owned 7,959 shares of the biotechnology company’s stock after selling 16,113 shares during the period. AlphaQuest LLC’s holdings in REGENXBIO were worth $62,000 as of its most recent SEC filing. […] - 2025-03-20 06:13:10
HC Wainwright Issues Pessimistic Forecast for REGENXBIO (NASDAQ:RGNX) Stock Price: REGENXBIO (NASDAQ:RGNX – Free Report) had its price target cut by HC Wainwright from $36.00 to $34.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other equities analysts also recently weighed in on RGNX. The Goldman Sachs Group […] - 2025-03-18 03:54:45
REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by New York State Common Retirement Fund: New York State Common Retirement Fund decreased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 17.4% in the fourth quarter, HoldingsChannel reports. The firm owned 13,746 shares of the biotechnology company’s stock after selling 2,900 shares during the quarter. New York State Common Retirement Fund’s holdings in REGENXBIO were worth $106,000 […] - 2025-03-06 08:19:25
Brokerages Set REGENXBIO Inc. (NASDAQ:RGNX) Target Price at $33.45: Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target […] - 2025-02-28 04:43:06
REGENXBIO (NASDAQ:RGNX) Stock Rating Upgraded by StockNews.com: REGENXBIO (NASDAQ:RGNX – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday. RGNX has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of REGENXBIO […] - 2025-02-27 04:15:04
StockNews.com Downgrades REGENXBIO (NASDAQ:RGNX) to Sell: REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday. Several other research firms have also issued reports on RGNX. The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” […] - 2025-02-17 04:39:03
The Goldman Sachs Group Downgrades REGENXBIO (NASDAQ:RGNX) to Neutral: REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat reports. They presently have a $14.00 price objective on the biotechnology company’s stock, down from their prior price objective of $38.00. The Goldman Sachs Group’s […] - 2025-02-13 06:46:49
Raymond James Initiates Coverage on REGENXBIO (NASDAQ:RGNX): Raymond James assumed coverage on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research note issued to investors on Friday morning. The firm issued an outperform rating and a $27.00 price target on the biotechnology company’s stock. A number of other analysts have also commented on the company. StockNews.com lowered REGENXBIO from a “hold” […] - 2025-02-10 14:57:04

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) RGNX holdings

Date	Number of RGNX Shares Held	Base Market Value of RGNX Shares	Local Market Value of RGNX Shares	Change in RGNX Shares Held	Change in RGNX Base Value	Current Price per RGNX Share Held	Previous Price per RGNX Share Held
2025-11-11 (Tuesday)	33,744	USD 389,743	USD 389,743	0	USD 17,884	USD 11.55	USD 11.02
2025-11-10 (Monday)	33,744	USD 371,859	USD 371,859	87	USD -5,436	USD 11.02	USD 11.21
2025-11-07 (Friday)	33,657	USD 377,295	USD 377,295	0	USD 1,346	USD 11.21	USD 11.17
2025-11-06 (Thursday)	33,657	USD 375,949	USD 375,949	87	USD -13,799	USD 11.17	USD 11.61
2025-11-05 (Wednesday)	33,570	USD 389,748	USD 389,748	0	USD 1,679	USD 11.61	USD 11.56
2025-11-04 (Tuesday)	33,570	USD 388,069	USD 388,069	88	USD -13,380	USD 11.56	USD 11.99
2025-11-03 (Monday)	33,482	USD 401,449	USD 401,449	0	USD -26,116	USD 11.99	USD 12.77
2025-10-31 (Friday)	33,482	USD 427,565	USD 427,565	0	USD -1,674	USD 12.77	USD 12.82
2025-10-30 (Thursday)	33,482	USD 429,239	USD 429,239	440	USD 4,980	USD 12.82	USD 12.84
2025-10-29 (Wednesday)	33,042	USD 424,259	USD 424,259	176	USD -8,258	USD 12.84	USD 13.16
2025-10-28 (Tuesday)	32,866	USD 432,517	USD 432,517	0	USD -15,118	USD 13.16	USD 13.62
2025-10-27 (Monday)	32,866	USD 447,635	USD 447,635	0	USD 19,391	USD 13.62	USD 13.03

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RGNX by Blackrock for IE00BYXG2H39

Show aggregate share trades of RGNX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 87 11.810 10.860 10.955 USD 953 8.80
2025-11-06 BUY 87 11.795 11.000 11.079 USD 964 8.78
2025-11-04 BUY 88 11.955 11.375 11.433 USD 1,006 8.75
2025-10-30 BUY 440 13.260 12.750 12.801 USD 5,632 8.69
2025-10-29 BUY 176 12.840 13.400 13.344 USD 2,349 8.67
2025-10-22 SELL -348 12.190 12.990 12.910 USD -4,493 8.55 Loss of -1,517 on sale
2025-10-20 BUY 174 12.640 12.820 12.802 USD 2,228 8.50
2025-10-17 BUY 434 11.730 12.315 12.256 USD 5,319 8.49
2025-10-15 BUY 688 12.300 12.345 12.341 USD 8,490 8.46
2025-10-03 BUY 616 10.430 10.997 10.940 USD 6,739 8.44
2025-10-02 BUY 88 10.580 10.580 10.580 USD 931 8.43
2025-09-30 BUY 176 9.650 10.005 9.970 USD 1,755 8.41
2025-09-26 BUY 176 9.650 9.670 9.668 USD 1,702 8.40
2025-09-25 BUY 176 9.360 9.730 9.693 USD 1,706 8.39
2025-09-18 BUY 90 9.360 9.483 9.471 USD 852 8.38
2025-09-17 BUY 270 9.030 9.500 9.453 USD 2,552 8.37
2025-08-20 SELL -352 8.070 8.190 8.178 USD -2,879 8.37 Profit of 67 on sale
2025-07-30 BUY 348 8.750 9.320 9.263 USD 3,224 8.36
2025-07-17 SELL -174 8.690 8.950 8.924 USD -1,553 8.34 Loss of -101 on sale
2025-07-11 SELL -704 8.680 9.110 9.067 USD -6,383 8.34 Loss of -514 on sale
2025-07-07 BUY 264 8.430 8.783 8.748 USD 2,309 8.32
2025-07-02 BUY 4,840 8.620 8.790 8.773 USD 42,461 8.32
2025-06-11 BUY 178 10.200 10.636 10.592 USD 1,885 8.27
2025-06-10 BUY 178 9.810 10.131 10.099 USD 1,798 8.26
2025-06-04 SELL -89 10.080 10.580 10.530 USD -937 8.22 Loss of -206 on sale
2025-04-23 BUY 89 8.870 9.160 9.131 USD 813 7.96
2025-04-10 SELL -712 5.410 5.773 5.737 USD -4,085 8.13 Profit of 1,705 on sale
2025-04-08 SELL -89 5.310 6.270 6.174 USD -549 8.19 Profit of 179 on sale
2025-04-07 SELL -89 5.930 6.162 6.139 USD -546 8.22 Profit of 185 on sale
2025-04-04 SELL -450 6.290 6.545 6.520 USD -2,934 8.24 Profit of 774 on sale
2025-04-01 BUY 360 6.760 7.180 7.138 USD 2,570 8.27
2025-03-31 SELL -270 7.150 7.460 7.429 USD -2,006 8.28 Profit of 231 on sale
2025-03-21 BUY 3,591 8.240 8.370 8.357 USD 30,010 8.29
2025-03-14 SELL -1,232 6.720 7.820 7.710 USD -9,499 8.34 Profit of 771 on sale
2025-03-07 SELL -154 6.340 6.580 6.556 USD -1,010 8.49 Profit of 297 on sale
2025-03-04 SELL -77 5.920 5.970 5.965 USD -459 8.60 Profit of 203 on sale
2025-02-25 BUY 154 6.720 6.870 6.855 USD 1,056 8.78
2025-02-19 SELL -77 7.460 7.720 7.694 USD -592 8.89 Profit of 92 on sale
2025-02-13 BUY 231 7.320 7.330 7.329 USD 1,693 9.01
2025-02-12 BUY 77 7.200 7.300 7.290 USD 561 9.05
2025-02-11 BUY 308 7.330 7.510 7.492 USD 2,308 9.08
2024-12-30 SELL -3,535 7.230 7.500 7.473 USD -26,417 9.61 Profit of 7,554 on sale
2024-11-18 SELL -1,290 10.150 11.380 11.257 USD -14,522 9.58 Loss of -2,167 on sale
2024-11-08 SELL -86 11.160 11.700 11.646 USD -1,002 9.40 Loss of -193 on sale
2024-10-21 SELL -87 10.370 11.230 11.144 USD -970 0.00 Loss of -970 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	87	11.810	10.860	10.955	USD 953	8.80
2025-11-06	BUY	87	11.795	11.000	11.079	USD 964	8.78
2025-11-04	BUY	88	11.955	11.375	11.433	USD 1,006	8.75
2025-10-30	BUY	440	13.260	12.750	12.801	USD 5,632	8.69
2025-10-29	BUY	176	12.840	13.400	13.344	USD 2,349	8.67
2025-10-22	SELL	-348	12.190	12.990	12.910	USD -4,493	8.55 Loss of -1,517 on sale
2025-10-20	BUY	174	12.640	12.820	12.802	USD 2,228	8.50
2025-10-17	BUY	434	11.730	12.315	12.256	USD 5,319	8.49
2025-10-15	BUY	688	12.300	12.345	12.341	USD 8,490	8.46
2025-10-03	BUY	616	10.430	10.997	10.940	USD 6,739	8.44
2025-10-02	BUY	88	10.580	10.580	10.580	USD 931	8.43
2025-09-30	BUY	176	9.650	10.005	9.970	USD 1,755	8.41
2025-09-26	BUY	176	9.650	9.670	9.668	USD 1,702	8.40
2025-09-25	BUY	176	9.360	9.730	9.693	USD 1,706	8.39
2025-09-18	BUY	90	9.360	9.483	9.471	USD 852	8.38
2025-09-17	BUY	270	9.030	9.500	9.453	USD 2,552	8.37
2025-08-20	SELL	-352	8.070	8.190	8.178	USD -2,879	8.37 Profit of 67 on sale
2025-07-30	BUY	348	8.750	9.320	9.263	USD 3,224	8.36
2025-07-17	SELL	-174	8.690	8.950	8.924	USD -1,553	8.34 Loss of -101 on sale
2025-07-11	SELL	-704	8.680	9.110	9.067	USD -6,383	8.34 Loss of -514 on sale
2025-07-07	BUY	264	8.430	8.783	8.748	USD 2,309	8.32
2025-07-02	BUY	4,840	8.620	8.790	8.773	USD 42,461	8.32
2025-06-11	BUY	178	10.200	10.636	10.592	USD 1,885	8.27
2025-06-10	BUY	178	9.810	10.131	10.099	USD 1,798	8.26
2025-06-04	SELL	-89	10.080	10.580	10.530	USD -937	8.22 Loss of -206 on sale
2025-04-23	BUY	89	8.870	9.160	9.131	USD 813	7.96
2025-04-10	SELL	-712	5.410	5.773	5.737	USD -4,085	8.13 Profit of 1,705 on sale
2025-04-08	SELL	-89	5.310	6.270	6.174	USD -549	8.19 Profit of 179 on sale
2025-04-07	SELL	-89	5.930	6.162	6.139	USD -546	8.22 Profit of 185 on sale
2025-04-04	SELL	-450	6.290	6.545	6.520	USD -2,934	8.24 Profit of 774 on sale
2025-04-01	BUY	360	6.760	7.180	7.138	USD 2,570	8.27
2025-03-31	SELL	-270	7.150	7.460	7.429	USD -2,006	8.28 Profit of 231 on sale
2025-03-21	BUY	3,591	8.240	8.370	8.357	USD 30,010	8.29
2025-03-14	SELL	-1,232	6.720	7.820	7.710	USD -9,499	8.34 Profit of 771 on sale
2025-03-07	SELL	-154	6.340	6.580	6.556	USD -1,010	8.49 Profit of 297 on sale
2025-03-04	SELL	-77	5.920	5.970	5.965	USD -459	8.60 Profit of 203 on sale
2025-02-25	BUY	154	6.720	6.870	6.855	USD 1,056	8.78
2025-02-19	SELL	-77	7.460	7.720	7.694	USD -592	8.89 Profit of 92 on sale
2025-02-13	BUY	231	7.320	7.330	7.329	USD 1,693	9.01
2025-02-12	BUY	77	7.200	7.300	7.290	USD 561	9.05
2025-02-11	BUY	308	7.330	7.510	7.492	USD 2,308	9.08
2024-12-30	SELL	-3,535	7.230	7.500	7.473	USD -26,417	9.61 Profit of 7,554 on sale
2024-11-18	SELL	-1,290	10.150	11.380	11.257	USD -14,522	9.58 Loss of -2,167 on sale
2024-11-08	SELL	-86	11.160	11.700	11.646	USD -1,002	9.40 Loss of -193 on sale
2024-10-21	SELL	-87	10.370	11.230	11.144	USD -970	0.00 Loss of -970 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RGNX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	64,479	0	139,400	46.3%
2025-09-18	84,937	0	121,818	69.7%
2025-09-17	47,973	16	100,960	47.5%
2025-09-16	43,295	0	70,718	61.2%
2025-09-15	72,739	200	159,666	45.6%
2025-09-12	54,737	1,000	99,783	54.9%
2025-09-11	67,337	0	112,580	59.8%
2025-09-10	52,185	350	122,096	42.7%
2025-09-09	46,876	0	99,349	47.2%
2025-09-08	68,417	0	150,461	45.5%
2025-09-05	91,648	0	217,582	42.1%
2025-09-04	75,373	19,896	190,431	39.6%
2025-09-03	156,369	0	215,631	72.5%
2025-09-02	57,661	3,400	134,029	43.0%
2025-08-29	62,046	0	130,707	47.5%
2025-08-28	56,171	800	186,332	30.1%
2025-08-27	94,599	0	211,224	44.8%
2025-08-26	81,311	0	229,911	35.4%
2025-08-25	104,388	0	361,323	28.9%
2025-08-22	123,995	1,150	503,774	24.6%
2025-08-21	28,093	0	103,803	27.1%
2025-08-20	77,529	0	180,996	42.8%
2025-08-19	99,073	0	300,779	32.9%
2025-08-18	40,585	0	134,689	30.1%
2025-08-15	49,186	0	161,104	30.5%
2025-08-14	77,737	10	310,272	25.1%
2025-08-13	72,888	0	417,860	17.4%
2025-08-12	73,440	212	379,241	19.4%
2025-08-11	110,252	0	225,658	48.9%
2025-08-08	133,652	0	235,169	56.8%
2025-08-07	182,763	39	353,534	51.7%
2025-08-06	67,867	45	257,881	26.3%
2025-08-05	65,463	0	171,330	38.2%
2025-08-04	53,346	7,900	129,540	41.2%
2025-08-01	69,885	696	254,539	27.5%
2025-07-31	45,311	511	217,767	20.8%
2025-07-30	110,439	0	393,789	28.0%
2025-07-29	48,595	0	595,404	8.2%
2025-07-28	56,056	234	197,594	28.4%
2025-07-25	101,848	0	185,552	54.9%
2025-07-24	75,888	0	210,767	36.0%
2025-07-23	138,517	0	294,989	47.0%
2025-07-22	72,374	0	148,798	48.6%
2025-07-21	118,276	891	294,218	40.2%
2025-07-18	112,165	0	299,884	37.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE